Abstract: Psoriasis is a chronic inflammatory skin disorder that presents ongoing challenges in its management. Current therapeutic approaches, including topical agents, phototherapy, systemic immunomodulators, and biologics, focus on symptom alleviation and improving patients' quality of life. Nonetheless, several limitations exist, such as adverse effects associated with treatments, the emergence of resistance, high costs, and significant inter-individual variability in therapeutic responses. Recent advancements in psoriasis management show promise in developing novel therapeutic agents. Biologics targeting underexploited pathways, particularly interleukin-23 inhibitors like lebrikizumab, have shown superior efficacy profiles. Small molecule inhibitors, such as RORγt and ROCK2 inhibitors, have broadened the therapeutic landscape. Combination regimens, including biologics in conjunction with methotrexate, may enhance overall treatment efficacy. Innovations in topical drug delivery systems, particularly through the use of microneedles and nanoparticle-based carriers, provide the potential for improved therapeutic outcomes. Moreover, the integration of biomarkers and multi-omics approaches holds substantial promise for personalized treatment strategies, refining diagnostic precision and predicting treatment responses while guiding therapeutic decisions. Collaborating among researchers, clinicians, and industry stakeholders is crucial to translating these scientific advancements into clinical practice. By addressing existing challenges and leveraging these emerging therapies, we can significantly enhance the management of psoriasis and improve patient outcomes for this chronic condition.
Parashar et al. (2025) studied this question.